{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/03/3305858/29517/en/MannKind-Enters-Data-Rich-Development-Period-with-Completion-of-Randomization-in-Phase-1b-INFLO-1-Study-and-Enrollment-of-First-Patient-in-Phase-2-INFLO-2-Trial-for-Nintedanib-DPI-.html", "message": "News view counter 776901 successfully enlarged"}